Zevra Therapeutics (ZVRA) Competitors $12.01 -0.12 (-0.99%) Closing price 04:00 PM EasternExtended Trading$11.80 -0.21 (-1.75%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. RXRX, XENE, CNTA, KNSA, ARWR, BHC, IBRX, AGIO, IDYA, and BLTEShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Centessa Pharmaceuticals (CNTA), Kiniksa Pharmaceuticals International (KNSA), Arrowhead Pharmaceuticals (ARWR), Bausch Health Cos (BHC), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Recursion Pharmaceuticals Xenon Pharmaceuticals Centessa Pharmaceuticals Kiniksa Pharmaceuticals International Arrowhead Pharmaceuticals Bausch Health Cos ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Belite Bio Recursion Pharmaceuticals (NASDAQ:RXRX) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Do analysts recommend RXRX or ZVRA? Recursion Pharmaceuticals presently has a consensus price target of $7.00, suggesting a potential upside of 30.60%. Zevra Therapeutics has a consensus price target of $23.71, suggesting a potential upside of 97.45%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is RXRX or ZVRA more profitable? Zevra Therapeutics has a net margin of -226.78% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Recursion Pharmaceuticals' return on equity of -76.09% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-1,004.91% -76.09% -54.29% Zevra Therapeutics -226.78%-201.05%-53.55% Which has more risk and volatility, RXRX or ZVRA? Recursion Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Do insiders and institutionals have more ownership in RXRX or ZVRA? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, RXRX or ZVRA? Zevra Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$64.51M33.77-$463.66M-$1.78-3.01Zevra Therapeutics$23.61M27.81-$105.51M-$1.90-6.32 Does the media prefer RXRX or ZVRA? In the previous week, Recursion Pharmaceuticals had 10 more articles in the media than Zevra Therapeutics. MarketBeat recorded 15 mentions for Recursion Pharmaceuticals and 5 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.71 beat Recursion Pharmaceuticals' score of 0.14 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZevra Therapeutics beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$656.71M$2.41B$5.45B$9.68BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-6.3220.1630.0525.00Price / Sales27.81444.85378.2478.85Price / CashN/A165.0335.9458.58Price / Book16.234.128.145.68Net Income-$105.51M$31.61M$3.25B$265.58M7 Day Performance8.10%0.45%1.16%2.51%1 Month Performance3.98%2.41%2.82%1.88%1 Year Performance62.52%4.44%28.41%24.02% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.0543 of 5 stars$12.01-1.0%$23.71+97.5%+67.5%$656.71M$23.61M-6.3220Upcoming EarningsRXRXRecursion Pharmaceuticals2.2314 of 5 stars$5.68-4.5%$7.00+23.2%-15.1%$2.42B$58.84M-3.21400Earnings ReportAnalyst RevisionXENEXenon Pharmaceuticals3.0814 of 5 stars$30.50-0.1%$54.82+79.7%-16.7%$2.34B$9.43M-9.44210Positive NewsUpcoming EarningsOptions VolumeCNTACentessa Pharmaceuticals3.0552 of 5 stars$16.81-2.1%$28.10+67.2%+57.5%$2.29B$6.85M-9.29200Upcoming EarningsKNSAKiniksa Pharmaceuticals International3.4356 of 5 stars$31.98+5.7%$41.17+28.7%+37.9%$2.21B$423.24M799.70220Insider TradeARWRArrowhead Pharmaceuticals4.1982 of 5 stars$15.93+0.8%$43.71+174.4%-35.8%$2.18B$3.55M-11.38400News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionBHCBausch Health Cos4.6875 of 5 stars$5.71-3.1%$7.38+29.2%+10.1%$2.18B$9.63B21.9620,700IBRXImmunityBio2.1895 of 5 stars$2.37-3.7%$12.25+416.9%-42.3%$2.17B$14.74M-4.09590Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionAGIOAgios Pharmaceuticals4.1707 of 5 stars$35.00-6.0%$56.33+61.0%-12.9%$2.16B$36.50M3.18390High Trading VolumeIDYAIDEAYA Biosciences4.1855 of 5 stars$24.27-0.3%$48.09+98.1%-37.5%$2.13B$7M-6.7680News CoverageEarnings ReportAnalyst RevisionBLTEBelite Bio2.227 of 5 stars$65.72+1.1%$96.67+47.1%+49.9%$2.07BN/A-48.3210News Coverage Related Companies and Tools Related Companies Recursion Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Kiniksa Pharmaceuticals International Alternatives Arrowhead Pharmaceuticals Alternatives Bausch Health Cos Alternatives ImmunityBio Alternatives Agios Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Belite Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
